Noelia Nebot, PhD, GAICD
Founding Director
- 15+years in oncology drug development
- 2approved oncology medicines, Tafinlar and Mekinist
- 100,000+patients treated with those medicines
- 4health authority regions: US, Europe, Canada and Japan
Dr Nebot is the Founding Director of Conexias Advisory. With more than 15 years in oncology drug development, Noelia has held global roles at GSK and Novartis.
In those roles, Noelia led pharmacokinetic, bioanalytical and pharmacometric teams and directed global clinical pharmacology strategy. Noelia supported dose selection for Tafinlar and Mekinist, which reached blockbuster status in 2019 and have treated over 100,000 patients.
Dr Nebot has engaged health authorities in the US, Europe, Canada and Japan, and has worked on mRNA medicine development and genomics technologies.
Today Noelia advises biotech and medtech companies through Conexias, lectures at the University of Sydney School of Pharmacy and mentors researchers, with a particular focus on women and diverse people in STEM.
Expertise
- Clinical pharmacology study design
- Population PK/PD analysis
- Regulatory submission authoring
- Health authority engagement
Experience
- GSK and Novartis
- Led pharmacokinetic, bioanalytical and pharmacometric teams
- Directed global clinical pharmacology strategy
- Tafinlar and Mekinist reached blockbuster status in 2019, treating over 100,000 patients
Current roles
- Founding Director, Conexias Advisory
- Member of the Syntegrity Quantitative Clinical Pharmacology Collaborative
- Lecturer, University of Sydney School of Pharmacy
Education
- PhD in Pharmaceutical Sciences, University of Sydney
- PK/PD post-doctoral fellowship, GSK and University of North Carolina
- GAICD
